



**COMPANY ANNOUNCEMENT
21 July 2006**

**NeuroSolutions to trial and market Automated Slice Device with
Scientifica Ltd**

NeuroDiscovery Ltd (ASX: NDL) a neurology-focused research and development company, is pleased to announce its 100% subsidiary, NeuroSolutions Ltd (**NeuroSolutions**) has entered into an agreement with Scientifica Ltd (**Scientifica**) to trial an automated electrophysiology device (**SliceMaster**) over an initial period of 6 months.

The trialing and marketing of the SliceMaster by both companies is in response to the increasing demand for NeuroSolutions' electrophysiology services, the move towards automation of these services and the continued growth in the outsourcing market for such services.

The SliceMaster will be fully operational within six weeks and will be located at NeuroSolutions' facilities at the University of Warwick in the UK.

The unique Scientifica SliceMaster is a semi-automated system which allows one trained operator to run up to eight assays at one time. The SliceMaster system permits concurrent and independent recordings from up to eight tissue slices, thus improving throughput, statistical design, and reducing tissue use.

Scientifica are experts in electrophysiological equipment and offer a comprehensive range of instruments for the research community. Being at the forefront of technological research and development, they are constantly adding products to their range.

NeuroDiscovery Chairman, Dr Mark Treherne said, "We are delighted to be working with Scientifica and the SliceMaster will help us deliver more high quality electrophysiology data to our clients with a faster turn about. We always look forward to using the latest technology available to us and see Scientifica as an important strategic partner."

Scientifica Ltd Managing Director, Mark Johnson said, "We are excited to be collaborating with Neurosolutions who are recognised as one of the UK's most dynamic electrophysiology service providers. We are sure that the SliceMaster will surpass expectations."

-ENDS-

For further information please contact:

*David McAuliffe
Executive Director
NeuroDiscovery Ltd
Mobile: +61 8 408 994 313
macdavid@iinet.net.au*

Background Information

About NeuroDiscovery

NeuroDiscovery Ltd is an ASX listed neurology research and development company which owns 100% of NeuroSolutions Ltd (ASX Code NDL).

About NeuroSolutions

NeuroSolutions Limited is a profitable service company, applying its broad expertise and drug discovery platforms to become a leading provider of specialised electrophysiological assays to the biopharmaceutical industry. Electrophysiology is a specialised technique which is used to record electrical activity in membranes, cells or tissues. NeuroSolutions current clients include many other established pharmaceutical and biotechnology companies.

In parallel to running its service business, the Company is also exploiting its in house technologies and expertise for its own internal R&D and has a mature pipeline of programmes underway for the treatment of pain. During 2006 and 2007 the company intends to commence a Phase I and II clinical trial on its lead compound NSL-043 in partnership with Sosei Co Ltd, a listed Japanese biopharmaceutical company.